We expect to see more pack trade-offs in potato chips, soft drinks and cold cereal but we also see outsized pack trade-offs in coffee and granola, which implies two emerging trends in the GLP-1 population: a general decrease in snacking, even for snacks usually considered healthy, and overall collateral damage that is spreading to categories that should not be greatly affected by GLP-1 status. In addition to their impact on the retail food and beverage market, oral GLP-1 medications are expected to account for 20% of total GLP-1 drug sales by 2031, with a pill market that is estimated to grow from $3.2 billion in 2025 to $34.3 billion in 2031, according to GlobalData.
TB-500 (Thymosin Beta-4) is a naturally occurring, highly conserved 43-amino acid peptide present in virtually all nucleated cells
Safety and Side Effects For most people, taking 2,000 mg or less daily is safe and well-tolerated
Small vessel disease of not only the heart but also the eye is an evolving field of research
GLP-1 agonists could be the first effective treatment for OUD that does not act on the opioid receptor pathway